Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti–Tissue Factor Pathway Inhibitor Antibody, PF-06741086-Reference-Cited by-同舟云学术

Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti–Tissue Factor Pathway Inhibitor Antibody, PF-06741086

Published:2018-07 Issue:7 Volume:107 Page:1995-2004
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Parng Chuenlei,Singh Pratap,Pittman Debra D.,Wright Katherine,Leary Beth,Patel-Hett Sunita,Rakhe Swapnil,Stejskal James,Peraza Marjorie,Dufield Dawn,Murphy John E.,Webster Rob

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference30 articles.

1. Heterogeneity of plasma tissue factor pathway inhibitor;Broze;Blood Coagul Fibrinolysis,1994

2. TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes;Girard;Blood,2012

3. Biology of tissue factor pathway inhibitor;Wood;Blood,2014

4. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor:basic and clinical aspects;Kato;Arterisocler Thromb Vasc Biol,2002

5. Tissue factor pathway inhibitor: structure-function;Broze;Front Biosci,2012

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders;Research and Practice in Thrombosis and Haemostasis;2024-05

2. The current challenges faced by people with hemophilia B;European Journal of Haematology;2023-12-11

3. Early stage clinical trials for the treatment of hemophilia A;Expert Opinion on Investigational Drugs;2022-11-02

4. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection;International Journal of Molecular Sciences;2022-10-22

5. Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-Linking Antibody, for Prediction of Human Pharmacokinetics and Clinically Effective Dose;Journal of Pharmaceutical Sciences;2022-09